Abstract
Chlorambucil (CLB), which is well known as a therapeutic agent of leukemia and Hodgkin’s disease, has been reported to have anticancer effects against various cancer cells. However, hydrophobic CLB has many problems, including being inefficient and producing side effects because of its low solubility in water. For these reasons, we developed a pegylated-CLB (PCLB and mPCLB) prodrug nanoparticle, which demonstrated excellent dispersibility, high anticancer activity and superior intracellular uptake. These results suggest that PCLB and mPCLB prodrug can use as anticancer agents against various cancer cells.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
